HUMA Stock — Humacyte Inc.: Cash, EV, Pipeline

What they do

Humacyte, Inc. is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, and in the first quarter of 2025 commenced the United States commercial launch of our first FDA-approved product.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.45

Market cap

$124.5M

Cash

$79.9M

Enterprise value

$80.9M

Balance sheet

Cash	$79.9M
Debt	$36.3M
Net cash	$43.6M
Enterprise value	$80.9M
Basic shares	277.8M shares
Fully diluted shares	340.6M shares
Fully diluted market cap	$153.3M
Cash per share	$0.29
Quarterly burn	$22.1M
Cash runway	3.6 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

277.8M

Pre-funded warrants

0.0M

Options

20.0M

RSUs

—

Warrants

42.8M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

340.6M

Cap table as of 2026-08-10.

Price history

Loading HUMA daily closes…

Loading price history…

Next catalyst

Acellular Tissue Engineered Vessel (Symvess) · Jan 12 - Feb 23 in 27 mo · Phase 3 · Vascular Trauma; Arterial Injury; Arterial Bleeding

Recently reported

Acellular Tissue Engineered Vessel (ATEV) Phase 3 Positive · 2026-10-23

end stage renal disease (esrd)

Primary: Catheter-free days from access creation through 365 days, or until access abandonment, whichever occurs first (V012 Phase 3, NCT05908084; prespecified interim analysis of the first 80 patients) — Women implanted with the ATEV averaged 91 more catheter-free days over the first 12 months than women receiving an AV fistula (220.4 days compared to 129.3 days; p<0.001)

· Median time to functional access was 1.7 months with the ATEV compared to 5.3 months with an AV fistula

· Only approximately 65% of AV fistulas achieved functional maturation by Month 12

· Trial designed to enroll approximately 150 female hemodialysis patients, randomized 1:1 to ATEV or AV fistula

· Because the trial met its primary endpoint, enrollment was stopped

· Humacyte targets submission of a supplemental BLA to expand the Symvess (ATEV) label to AV access for hemodialysis this quarter

Safety: Safety profile comparable to AV fistula; dialysis access infections approximately 6 per 100 patient-years with the ATEV compared to 23 per 100 patient-years with AV fistula, none of the ATEV infections related to the vessel itself, and no spontaneous ruptures reported in either group

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23 in 27 mo	Acellular Tissue Engineered Vessel (Symvess)	Phase 3	Vascular Trauma; Arterial Injury; Arterial Bleeding	—
Oct 13 - Nov 24 in 48 mo	Humacyte Coronary Tissue Engineered Vessel (CTEV)	Phase 2	Coronary Artery Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Symvess

Approved · Active Modality: regenerative medicine (bioengineered vessel)

Aliases acellular tissue engineered vessel, ATEV

Partnerships Fresenius Medical Care (agreement to sell, market and distribute 6mm ATEV for specified indications and markets, if approved); Kingdom of Saudi Arabia (commitment to purchase Symvess for clinical evaluation and outreach program)

Indications

extremity vascular trauma (Approved)

Status note Commercial product. ATEV assigned a priority designation by the Secretary of Defense under Public Law 115-92 (2018) to expedite FDA review for conditions facing military personnel.

ATEV (AV access program)

Phase 3 · Active Modality: regenerative medicine (bioengineered vessel)

Indications

arteriovenous access for hemodialysis (Phase 3)

Catalysts

— H2 2026

Status note Ongoing V007 and V012 Phase 3 trials in AV access for hemodialysis. V012: prospective randomized blinded trial, target 150 women, 113 enrolled, interim analysis planned on first 80 patients after one year of follow-up. Targeting patients at high risk of fistula failure/non-maturation.

BVP

Preclinical · Active Modality: regenerative medicine (bioengineered vessel)

Aliases biovascular pancreas

Partnerships Yale University (worldwide patent license, Aug 2019); Breakthrough T1D / JDRF (Industry Discovery and Development Partnership, Apr 2023, for preclinical development and testing)

Indications

type 1 diabetes (Preclinical)

Status note Biovascular pancreas designed to deliver insulin-producing islets using the ATEV as a means of treating type 1 diabetes.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Acellular Tissue Engineered Vessel
Lead indication	Vascular Injury
Lead phase	Phase 4
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05908084	Phase 3	Active, not recruiting	Sponsor	HUMA	—	End Stage Renal Disease (ESRD)	H2 2026 Est. Nov 7, 2026 · half midpoint
NCT07762313	Phase 3	Not yet recruiting	Sponsor	HUMA	—	Vascular Trauma; Arterial Injury; Arterial Bleeding	—
NCT07730528	Phase 2	Not yet recruiting	Sponsor	HUMA	—	Coronary Artery Disease	—
NCT07762794	Not disclosed	Not yet recruiting	Sponsor	HUMA	—	Vascular Injury; Arterial Injury; Trauma Injury	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Humacyte, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Great Point Partners	3,750,000	no change	0.69%	2026-08-14
Stonepine Capital	231,299	+231,299	0.14%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

HUMA — Humacyte Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

HUMA — Humacyte Inc.